Want to see AU:ILA full AI Analyst Report?
Top Page
Island Pharmaceuticals Ltd
(Sydney:ILA)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.28
â–¼(-36.82% Downside)
Action:Reiterated
Date:10/31/26
The score is pressured primarily by weak financial performance (minimal/zero revenue, widening losses, and persistent cash burn) and a bearish technical trend (price below all key moving averages with negative MACD). The key support is a low-debt balance sheet with increased equity, which helps reduce near-term solvency risk, but valuation is not compelling on an earnings basis due to ongoing losses and no dividend yield data.
Positive Factors
Debt-Free Balance Sheet
The absence of reported debt limits interest obligations and refinancing exposure, giving the company greater flexibility while it advances its pipeline. A debt-free structure can help preserve scarce capital for research, clinical development, and regulatory activities over the next several quarters.
Negative Factors
No Current Revenue Base
The absence of reported revenue leaves the company dependent on successful clinical and regulatory execution before it can establish a commercial income stream. This increases reliance on capital markets or other funding sources and makes financial performance highly sensitive to development outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
The absence of reported debt limits interest obligations and refinancing exposure, giving the company greater flexibility while it advances its pipeline. A debt-free structure can help preserve scarce capital for research, clinical development, and regulatory activities over the next several quarters.
Read all positive factors
Island Pharmaceuticals Ltd (ILA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$85.87M
Dividend YieldN/A
Average Volume (3M)225.41K
Price to Earnings (P/E)―
Beta (1Y)-0.68
Revenue GrowthN/A
EPS Growth-59.29%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding296,096,680
10 Day Avg. Volume180,032
30 Day Avg. Volume225,408
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)7.63
Price to Sales (P/S)0.00
P/FCF Ratio-21.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)N/A
Island Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections. Its lead therapeutic agent, ISLA-101...
Island Pharmaceuticals Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 118.91K | 1.25M | 11.06K | 0.00 |
| Gross Profit | -105.29K | -1.29M | -1.01M | 11.06K | 0.00 |
| EBITDA | -10.51M | 0.00 | -2.82M | 86.68K | 202.12K |
| Net Income | -9.84M | -3.92M | -2.86M | -2.83M | -2.61M |
Balance Sheet | |||||
| Total Assets | 14.00M | 7.49M | 2.56M | 2.05M | 4.90M |
| Cash, Cash Equivalents and Short-Term Investments | 12.87M | 7.25M | 1.66M | 2.00M | 4.79M |
| Total Debt | 0.00 | 0.00 | 421.97K | 0.00 | 0.00 |
| Total Liabilities | 538.52K | 336.43K | 1.05M | 263.85K | 580.73K |
| Stockholders Equity | 13.46M | 7.16M | 1.52M | 1.79M | 4.32M |
Cash Flow | |||||
| Free Cash Flow | -4.83M | -2.77M | -3.16M | -2.71M | -1.88M |
| Operating Cash Flow | -4.83M | -2.77M | -3.16M | -2.71M | -1.88M |
| Investing Cash Flow | -841.70K | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 11.11M | 8.36M | 2.79M | -171.36K | 0.00 |
Island Pharmaceuticals Ltd Technical Analysis
Negative
0.44
Price Trends
0.39
Negative
0.40
Negative
0.39
Negative
Market Momentum
-0.02
Positive
27.34
Positive
30.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ILA, the sentiment is Negative. The current price of 0.44 is above the 20-day moving average (MA) of 0.34, above the 50-day MA of 0.39, and above the 200-day MA of 0.39, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 27.34 is Positive, neither overbought nor oversold. The STOCH value of 30.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ILA.
Island Pharmaceuticals Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$153.48M | -1.61 | -1189.87% | ― | 53.78% | -206.24% | |
47 Neutral | AU$126.08M | -4.23 | 362.74% | ― | -22.13% | -108.82% | |
45 Neutral | AU$110.10M | -6.95 | 84.67% | ― | ― | 42.51% | |
44 Neutral | AU$162.72M | -8.75 | -103.42% | ― | ― | 5.88% | |
44 Neutral | AU$33.90M | -0.43 | -98.86% | ― | ― | -27.73% | |
42 Neutral | AU$85.87M | -8.06 | -95.50% | ― | ― | -59.29% |
* Healthcare Sector Average
AU:ILA
Island Pharmaceuticals Ltd
0.29
-0.14
-32.56%
AU:ACW
Actinogen Medical
0.04
<0.01
20.00%
AU:PAR
Paradigm Biopharmaceuticals
0.25
-0.18
-42.35%
AU:IMM
Immutep Ltd
0.02
-0.26
-91.79%
AU:DXB
Dimerix Limited
0.21
-0.30
-58.82%
AU:RCE
Recce Pharmaceuticals Ltd.
0.36
-0.07
-15.29%
Island Pharmaceuticals Ltd Corporate Events
Island Pharmaceuticals advances Galidesivir program with Ebola use, Marburg studies and expanded manufacturing
Oct 25, 2026
Island Pharmaceuticals reported strong progress in the September quarter on its Galidesivir program, securing government and regulatory approvals for compassionate use in Uganda’s Bundibugyo Ebola outbreak and creating a rare opportunity to ...
Island Pharmaceuticals Sets In-Person AGM and Pushes Paperless Communications
Oct 22, 2026
Island Pharmaceuticals has called its Annual General Meeting for 24 November 2026 in Sydney, with shareholders required to attend in person as there will be no virtual access. The company is encouraging investors to lodge directed proxy votes and ...
Island Pharmaceuticals Expands Unquoted Employee Options Pool
Oct 9, 2026
Island Pharmaceuticals Ltd is an ASX-listed biotechnology company focused on developing pharmaceutical products. The company uses equity-based employee incentive schemes as part of its broader capital management and talent retention strategy in th...
Island Pharmaceuticals ramps up Galidesivir production for Ebola and Marburg programs
Oct 2, 2026
Island Pharmaceuticals has begun GMP manufacturing of the antiviral Galidesivir at PI Health Sciences, with the first 5kg batch due by the end of October to support an emergency-use program in Uganda amid the Bundibugyo Ebola outbreak. The drug, a...
Island Pharmaceuticals Reschedules AGM and Updates Director Nomination Deadline
Sep 30, 2026
Island Pharmaceuticals Ltd has rescheduled its Annual General Meeting, reflecting routine corporate governance adjustments as it advances its antiviral drug portfolio aimed at serious viral and biosecurity threats. The AGM will now take place on 2...
Island Pharmaceuticals Secures Key Marburg Data to Advance Galidesivir FDA Pathway
Aug 31, 2026
Island Pharmaceuticals has secured a Letter of Authorisation granting access to detailed non-human primate natural history data for the Marburg-Angola virus, a key requirement for U.S. Food and Drug Administration submissions under the Animal Rule...
Island Pharmaceuticals files updated ASX corporate governance statement
Aug 26, 2026
Island Pharmaceuticals Ltd has lodged its updated corporate governance statement for the financial year ended 30 June 2026, confirming that the document is current as of that date and has been approved by the board. The statement is hosted on the ...
Island Pharmaceuticals Posts Larger Loss as Net Tangible Assets Improve in FY2026
Aug 26, 2026
Island Pharmaceuticals reported a sharp increase in income from ordinary activities to $559,080 for the year ended 30 June 2026, up 214.6% from the prior year, reflecting modest revenue generation in its biotech operations. Despite this, the group...
Island Pharmaceuticals boosts Galidesivir supply as Bundibugyo Ebola outbreak escalates
Aug 20, 2026
Island Pharmaceuticals has commissioned a second manufacturing campaign of GMP-grade Galidesivir with PI Health Sciences to materially expand its available drug inventory. The company expects to have around 700 to 800 treatment courses ready by th...
Island Pharmaceuticals Sets October AGM and Board Nomination Deadline
Aug 13, 2026
Island Pharmaceuticals has scheduled its Annual General Meeting for 8 October 2026 in Melbourne, with the agenda to include the re-election of directors as part of its regular corporate governance cycle. The company has set 5:00 p.m. Melbourne tim...
Island Pharmaceuticals Issues New Shares on Option Exercise and Confirms Regulatory Compliance
Aug 11, 2026
Island Pharmaceuticals has issued 180,000 fully paid ordinary shares following the exercise of unlisted options at an issue price of $0.12 per share. The company confirmed that these shares were issued without the need for a disclosure document an...
Island Pharmaceuticals Seeks ASX Quotation for Additional Shares
Aug 11, 2026
Island Pharmaceuticals Ltd, an ASX-listed biopharmaceutical company trading under the code ILA, is engaged in the development of pharmaceutical products. The firm operates within the life sciences sector and uses public equity issuance as a key fu...
Island Pharmaceuticals Targets Filovirus Threats With Galidesivir Strategy
Aug 6, 2026
Island Pharmaceuticals has outlined a dual approach to advance its antiviral candidate Galidesivir as a pan-filovirus medical countermeasure. The strategy is framed against the backdrop of past Ebola outbreaks, highlighting the scale of cumulative...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.